Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and Therapy
Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and Therapy
批准号:
10666459
负责人:
Jerry Edward Chipuk
金额:
$48.26万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-07-15 至 2027-05-31
关键词:
AddressAntibodiesBiological AssayBiologyCancer BiologyCancer PrognosisCell DeathCell Death InductionCell LineCell SurvivalCellsChronicClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplexDataDermatologyDetectionDevelopmentDiseaseEventFDA approvedFunctional disorderGenerationsGenesGenomicsGoalsHeterogeneityHomeostasisHumanKnowledgeLaboratoriesLinkMAP Kinase GeneMalignant - descriptorMalignant NeoplasmsMelanoma CellMetabolicMetabolismMitochondriaMitochondrial DNAModelingMolecularMonoclonal AntibodiesMusMutationNatureNeoplasm MetastasisOncogenesOncogenicOrganellesPathogenesisPathway interactionsPhenotypeProcessPrognosisProliferatingPublishingRNA InterferenceRegulationResourcesRiskSignal TransductionTherapeuticWorkcancer cellcancer therapycancer typeimprovedinsightloss of functionmelanocytemelanomamelanomagenesismetabolomicsmetaplastic cell transformationmitochondrial DNA mutationmitochondrial dysfunctionnext generationnovelpharmacologicpreventprognosticprognostic assaysprognostic valuesmall moleculesuccesstargeted treatmenttooltumor metabolismtumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
The impact of mitochondrial biology on human cancers is broad because these organelles are critical regulators
of metabolism, proliferation, metastasis, and cell death. Indeed, mitochondrial aberrations are common in
multiple cancer types – not only do mitochondrial dysfunctions correlate with disease pathogenesis, but aberrant
mitochondria also negatively impact upon chemotherapeutic success. Within a cell, mitochondrial homeostasis
is maintained by a process referred to as “mitochondrial dynamics”, which is essential for efficient ATP
generation, mitochondrial metabolites/substrates distribution, and mitochondrial DNA (mtDNA) integrity.
Homeostatic mitochondrial dynamics result from the cumulative nature of complementary cycles of mitochondrial
division and fusion. Work from my laboratory demonstrates: (1) the mitochondrial division machinery is essential
for cellular transformation, (2) mitochondrial division is chronically activated in RAS-transformed murine cells
and human cancer lines harboring oncogenic mutations within the MAPK pathway, (3) chronic mitochondrial
division is sufficient to initiate mitochondrial dysfunction and cancer cell metabolism, and (4) FDA-approved
targeted therapies that inhibit oncogenic MAPK signaling turn off the mitochondrial division machinery. While the
above studies link chronic mitochondrial division to cancer biology, mechanistic explanations for how chronic
mitochondrial division promotes organelle dysfunction and cancer phenotypes are scarce. In this R01
application, our goals are to (1) provide key mechanistic details into the process and contributions of
mitochondrial dysfunction during oncogenic transformation, and (2) develop novel translational tools focused on
the detection and inhibition of chronic mitochondrial division to enhance cancer prognosis and treatment. As our
expertise and resources are in dermatology, we will focus on melanoma. The presence of mtDNA mutations and
mitochondrial aberrations in cancer have been described for decades, but the molecular events that drive these
changes and their impact on cancer biology remain speculative. To address this knowledge gap, we recently
completed an unbiased screen using normal melanocytes and melanoma cell lines to understand how chronic
mitochondrial division impacts on mitochondrial function, and identified that loss-of-function mtDNA mutations
are essential for cancer cell metabolism, proliferation, and tumorigenesis. We hypothesize that oncogene-
induced chronic mitochondrial division promotes mtDNA mutations and organelle heterogeneity to instigate
transformation. Based on our data, chronic mitochondrial division is an early event during melanomagenesis,
and provides strong prognostic value and therapeutic potential. This project emerged following years of effort to
identify how chronic mitochondrial division impacts cancer mechanisms, prognosis, and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chronic Mitochondrial Division and Melanoma: Mechanism, Prognosis, and Therapy
-
批准号:10464554
-
项目类别:
-
资助金额:$49.24万
-
财政年份:2022
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and Regulation of the BCL-2 Family
-
批准号:10334546
-
项目类别:
-
资助金额:$37.89万
-
财政年份:2020
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and Regulation of the BCL-2 Family
-
批准号:10576308
-
项目类别:
-
资助金额:$37.89万
-
财政年份:2020
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and Regulation of the BCL-2 Family
-
批准号:9889679
-
项目类别:
-
资助金额:$38.66万
-
财政年份:2020
-
负责人:Jerry Edward Chipuk
-
依托单位:
(PQ5) Role of Mitochondrial Division in Cancer Biology
-
批准号:9888358
-
项目类别:
-
资助金额:$35.12万
-
财政年份:2016
-
负责人:Jerry Edward Chipuk
-
依托单位:
(PQ5) Role of Mitochondrial Division in Cancer Biology
-
批准号:9256448
-
项目类别:
-
资助金额:$35.12万
-
财政年份:2016
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and regulation of the BCL-2 family
-
批准号:8268982
-
项目类别:
-
资助金额:$35.04万
-
财政年份:2011
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and regulation of the BCL-2 family
-
批准号:8633008
-
项目类别:
-
资助金额:$33.99万
-
财政年份:2011
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and regulation of the BCL-2 family
-
批准号:8461469
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2011
-
负责人:Jerry Edward Chipuk
-
依托单位:
Function and regulation of the BCL-2 family
-
批准号:8080602
-
项目类别:
-
资助金额:$35.04万
-
财政年份:2011
-
负责人:Jerry Edward Chipuk
-
依托单位:
Non-transcriptional Mechanisms of p53-mediated Apoptosis
-
批准号:7175273
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2003
-
负责人:Jerry Edward Chipuk
-
依托单位:
Non-transcriptional Mechanisms of p53-mediated Apoptosis
-
批准号:6793988
-
项目类别:
-
资助金额:$4.73万
-
财政年份:2003
-
负责人:Jerry Edward Chipuk
-
依托单位:
海外基金